ClinicalTrials.gg
CompletedNCT05192616iliCoUpdated Nov 5, 2026

Safety and Effectiveness Evaluation of iCover Covered Stent for the Treatment of the Aorto-iliac Occlusive Disease

An observational study in Angioplasty, Peripheral Arterial Disease and Iliac Artery Disease, sponsored by iVascular S.L.U.. Completed at 18 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by iVascular S.L.U. · Observational

How we know

Updated Nov 5, 2026Now CompletedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
241
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 120 studies in Peripheral Arterial Disease with a site in France — 21 open to participants now, 27 under way, 4 of them phase 3. Peripheral Arterial Disease · France.

Enrollment
31st of 54
241 · median 298
Started
2022
with 6 others
Observational
54 of 120
8 open now
Registered
95th of 120
by date

Among the 120 studies in Peripheral Arterial Disease with a site in France, this one is the 31st largest by enrollment of the 54 observational ones that give a count, is one of 7 that started in 2022, is one of 54 observational ones, and was the 95th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

21 of the 120 studies in Peripheral Arterial Disease with a site in France are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Peripheral Arterial Disease with a site in France, or all of them as a file.
02

Study summary

The objective of this prospective, multi-center, non-randomized, single-arm observational study is to evaluate the safety and the efficacy of the iCover covered stent over a 24-month follow-up period for the treatment of de novo iliac occlusive lesions, defined by a significant vessel stenosis ≥70%, in patients with symptomatic arteriopathy of the lower limbs (Rutherford class 2 to 5).

Read the detailed description

This is a prospective, single-arm, multinational, and multicenter study conducted to evaluate the safety and efficacy of the iCover covered stent for the treatment of de novo iliac occlusive lesions (common and/or external iliac arteries) in patients with symptomatic lower limb arteriopathy. The primary endpoint of the study is primary patency, defined as the absence of restenosis in the target lesion over a 12-month follow-up period in patients who did not undergo a reintervention on the target lesion. Restenosis is defined as a reduction in the luminal diameter of more than 50%, assessed either by duplex ultrasound (considered as a peak systolic velocity index ≥ 2.4 at the target lesion) or by angio-CT (multiplanar reconstruction). Secondary endpoints include: technical and procedural success rate, freedom from all major adverse events, incidence of procedure- or device-related major local complications at the treated lesion, rate of SAEs, major amputation rate at the target limb, primary sustained clinical improvement (improvement in Rutherford classification), primary and secondary patency rates, TLR and TVR rates, and changes in ABI, the Walking Impairment Questionnaire, and the EQ-5D questionnaire from baseline.

03

Conditions studied

  • Angioplasty
  • Peripheral Arterial Disease
  • Iliac Artery Disease
  • Covered Stent
  • Aorto-Iliac Atherosclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with symptomatic arteriopathy of the lower limbs (Rutherford class 2 to 5). Patients with de novo atheromatous aorto-iliac lesions.

According to the incidence of TASC II lesions, approximately 70% of the patients will be classified as TASC II A or B lesions, while the other 30% will be classified as TASC II C or D lesions.

Eligibility criteria

Inclusion criteria

  1. ≥ 18 years of age
  2. Rutherford clinical stage 2 to 5
  3. Significant (≥70%) stenosis of atheromatous iliac lesions evidenced by duplex scan, MRI CT angiography or arteriography
  4. De novo atheromatous lesion of the aortoiliac segment
  5. Patient informed about the study and collection of the patient's agreement Exclusion criteria

Subjects will not be eligible to participate in the study if any of the following conditions are present in the subject:

  1. Protected adult patients, guardianship, curatorship, safeguard of justice
  2. Woman with possibility of pregnancy
  3. Patient with asymptomatic atheromatous lesions
  4. Patient with inflow lesion in the infrarenal aorta
  5. Patient treated with Covered endovascular reconstruction of aortic bifurcation (CERAB reconstruction)
  6. Acute ischemia or acute thrombosis
  7. Non-atherosclerotic disease
  8. History of coagulopathy
  9. Severe comorbidities with \<2 years
  10. to taking antiplatelet aggregation therapy (aspirin or clopidogrel). The patient must be able to take an antiplatelet aggregation for at least 3 months after the procedure
  11. Patient participating in another clinical study which may interfere with the results
  12. Comorbidity or any reason which, according to the investigator, could limit the participation, the patient's adherence with the follow-up or the scientific integrity of the study
  13. Lesion near or adjacent to an aneurysm
  14. Inability to follow-up during the investigation
  15. Patient objection to participate in the investigation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
241 participants (actual)
Patient registry
No

Groups and cohorts

  • iCover covered stent

    Percutaneous transluminal angioplasty (PTA)

    Device: Covered stent implantation

Interventions

  • DeviceCovered stent implantation

    Percutaneous transluminal angioplasty (PTA) with iCover covered stent for the treatment of de novo aorto-iliac occlusive lesions

06

What researchers measure

Primary outcomes

  1. Primary Patency

    The primary patency, defined as the absence of restenosis in the target lesion over the 12-month follow-up period in patients who did not undergo a reintervention on the target lesion.

    Time frame: 12 months after index procedure.

Secondary outcomes

  1. Technical success rate

    Technical success rate, defined as the ability to cross and dilate the lesion and achieve residual angiographic stenosis no greater than 30% after iCover stent graft insertion. Outcomes will be computed as the percentage of lesions treated at the end of the procedure.

    Time frame: Day 0.

  2. Procedural success rate

    Procedural success rate, defined as technical success and no complications during the procedure including general and local complications as defined in the protocol. Outcomes will be computed as the percentage of patients at the end of the procedure.

    Time frame: Day 0.

  3. Freedom from All Major Adverse Event (MAEs)

    MAEs are described as All-Cause Mortality post-procedure, Target Lesion Revascularization (TLR) post-procedure and Major Amputation of the Target Limb post-procedure (amputations above the ankle of the target leg).

    Time frame: 1, 6, 12, 24 months after index procedure.

  4. Incidence of Procedure- or Device- related Major Local Complications

    Incidence of Procedure- or Device- related Major Local Complications at the treated lesion or Puncture Site up to 30 days post-procedure. Major Local Complications include: Iliac arterial rupture, retroperitoneal hematoma, thrombosis of the iliac axis on the ipsilateral side, need for surgery to achieve hemostasis, bleeding with loss of more than 2 g/ dL of hemoglobin, false aneurysm at the puncture site, preventing resumption of walking at 24 hours or appearance of ischemia on the ipsilateral side.

    Time frame: Up to 30 days after index procedure.

  5. Rates of Serious Adverse Events (SAEs)

    Rates of SAEs, including both related and unrelated events. SAEs will be categorized as related or unrelated to the procedure/device based on adjudication by an Independent Clinical Events Committee.

    Time frame: 1, 6, 12, 24 months after index procedure.

  6. Major amputation at target limb rate

    Percentage of patients with amputations above the ankle of the target leg will be counted.

    Time frame: 1, 6, 12, 24 months after index procedure.

  7. Primary sustained clinical improvement

    Primary sustained clinical improvement defined as a sustained upward shift of 1 category of the Rutherford classification for patients with claudication, and by wound healing and rest pain resolution for patients in critical limb ischemia, without the need for repeated target lesion revascularization in surviving patients.

    Time frame: 1, 6, 12, 24 months after index procedure.

  8. Primary patency rates

    Primary patency rates, defined as the lack of restenosis without reintervention of the target lesion. Restenosis is defined as a reduction in the luminal diameter of more than 50%, determined by either, duplex ultrasound examination considered as a peak systolic velocity index ≥ 2.4 at the target lesion, or by angio-CT (multiplanar reconstruction). In case of death, the vessel is considered as patent as long as no restenosis was detected during the last visit before the patient died. Outcomes will be computed as the percentage of lesions (Time frame: 6, 24 months after index procedure).

    Time frame: 6 and 24 months after index procedure.

  9. Secondary patency rates

    Secondary patency rates, defined as the patency of the stent following an endovascular or surgical reintervention due to significant in-stent restenosis or occlusion. Outcomes computed as percentage of lesions.

    Time frame: 6, 12, 24 months after index procedure.

  10. Target lesion revascularization (TLR) rate

    Target lesion revascularization (TLR) rate, defined as the need for repeated procedures (endovascular or surgical) due to a problem arising from the lesion initially treated in surviving patients with preserved limbs. Outcomes will be computed as the percentage of lesions.

    Time frame: 1, 6, 12, 24 months after index procedure.

  11. Target vessel revascularization (TVR) rate

    Target vessel revascularization (TVR) rate, defined as the need for repeated procedures (endovascular or surgical) due to a problem arising remote from the vessel initially treated in surviving patients with preserved limbs. Outcomes will be computed as the percentage of lesions.

    Time frame: 1, 6, 12, 24 months after index procedure.

  12. Change in Ankle-Brachial Index (ABI) from baseline

    Change in ABI from baseline.

    Time frame: 1, 6, 12, 24 months post-procedure.

  13. Change in Walking Impairment Questionnaire from baseline

    The Walking Impairment Questionnaire values will be recorded and compared to the baseline values. This questionnaire is a validated tool to assess walking capability in patients with Peripheral Arterial Disease in different situations.

    Time frame: 1, 6, 12, 24 months post-procedure.

  14. Change in quality of life from baseline

    Change in quality of life from baseline, as measured by EQ-5D. The EQ-5D Questionnaire values will be recorded and compared to the baseline values. It is a validated questionnaire to measure the quality of life based on 5 different parameters. Worst possible score in this study would be 0, best possible score would be 1. In addition, the patient indicates her/his current health on an analog scale from 0 (worst) to 100 (best).

    Time frame: 1, 6, 12, 24 months post-procedure.

07

Study locations

18 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jun 2025, 38 months.

Of 58 industry-sponsored observational studies under Peripheral Arterial Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 38 months is above that.

Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Sep 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2021
First posted
Jan 14, 2022
StartActual
Apr 27, 2022
Primary completionActual
Jun 30, 2025
CompletionActual
Sep 30, 2026was Jun 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 5, 2026
Sites
1 site added, 1 site removed
Show site
  • Herzzentrum Bad Krozingen · Bad Krozingen, Germany
Show 1 removed
  • Herzzentrum Bad Krozingen · Bad Krozingen, Germany
Nov 5, 2026
Study completion
Jun 2026→Sep 30, 2026 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Active, not recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Herzzentrum Bad Krozingen · Bad Krozingen, Germany
    Show 1 removed
    • Herzzentrum Bad Krozingen · Bad Krozingen, Germany
    Study completion Jun 2026→Sep 30, 2026 (now actual)
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05192616
Lead sponsor
iVascular S.L.U.
Responsible party
Sponsor
First posted
Jan 14, 2022
Start date
Apr 27, 2022
Primary completion
Jun 30, 2025
Completion
Sep 30, 2026
Last update
Nov 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion